Knowledges and Use of Cannabidiol in Older Adults

Aging Clinical Trial

— CBD-65  

Official title:

Knowledges and Use of Cannabidiol in Older Adults Aged 65 Years and Over in France

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06094582
• Other study ID #: RC31/23/0494
• Secondary ID: 2023-A02080-45
• Status: Recruiting
• Start date: October 26, 2023
• Est. completion date: May 2024

Study information

• Verified date: April 2024
• Source: University Hospital, Toulouse
• Contact: Sandrine SOURDET, MD
• Phone: 05 61 77 79 29
• Email: sourdet.s[@]chu-toulouse.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The use of non-medical cannabidiol (CBD) has been growing recently in France and in the world, in young but also older adults. Few data are available on the use of cannabidiol in older adults. A better knowledge of the use of cannabidiol in older adults, and of their own knowledges of the molecule, is necessary to guide and follow the CBD uptake in this population and avoid potential adverse events.

Description:

Cannabidiol may be used by patients because it may have beneficial pharmacological effects (including anxiolytic, analgesic, anti-inflammatories or antioxidant effects). Older adults aged 65 years and over, are more frequently at risk of multimorbidity and loss of autonomy, and may present with several symptoms like pain, anxiety, sleep disturbances, that may potentially respond to CBD. The molecule is often marketed as devoid of adverse effects. Nevertheless, with ageing, reduction in liver and kidney function, may have an impact on the metabolism and elimination of CBD and increase the risk of side-effect. As well, the risk of interaction with drugs frequently prescribed in older adults such as CYP3A4 inhibitors (verapamil, ketoconazole …), CYP3A4 inducers (phenytoin, carbamazepine, …) or CY92C19 inhibitors or inducers (fluoxetine …), may increase the risk of side effects. Our hypothesis is that the use of CBD has increased last years in older adults, but that they are insufficiently informed about this molecule. There is a need to assess the prevalence of CBD use in older adults in France, to assess the knowledges of CBD users about this substance, and to better characterize CBD users.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 140
• Est. completion date: May 2024
• Est. primary completion date: May 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years to 120 Years

Eligibility

Inclusion Criteria:

• admitted to the frailty clinic, in Toulouse University Hospital during the recruitment period.

Exclusion Criteria:

• major cognitive disorder with Mini Mental State Examination <20

• being under legal supervision or guardianship.

Related Conditions & MeSH terms

• Aging
• Frailty

Intervention

Other:
• questionnaire
Participants will have to fulfill a short questionnaire (10 minutes) concerning their use and knowledges about CBD.

Locations

Country	Name	City	State
France	University Hospital Toulouse	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of CBD use (having consumed CBD at least once)	The patient will complete a questionnaire about CBD use	1 day